Covid 19 Research using Clinical Trials (Home Page)
Report for D009205: Myocarditis NIH
(Synonyms: Myocarditis)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (4)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1328 | laboratory biomarkers Wiki | 0.71 |
| drug838 | Performing routine care (clinical and paraclinical tests) Wiki | 0.71 |
| drug419 | Examinations for the research: Wiki | 0.71 |
| drug1349 | muscle ultrasound Wiki | 0.71 |
Correlated MeSH Terms (4)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D009220 | Myositis NIH | 0.71 |
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.03 |
Correlated HPO Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012819 | Myocarditis HPO | 1.00 |
| HP:0100614 | Myositis HPO | 0.71 |
There are 2 clinical trials
Clinical Trials
1 Prospective Registry for Multimodal Assessment of Neuromuscular Pathology Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Prospective registry for multimodal assessment of neuromuscular pathology associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, enrolling consecutive patients with corona virus disease 2019 (Covid-19), who are admitted to the intensive care unit of the department of anesthesiology and intensive care medicine, or the department of neurology at Tübingen University Hospital.
NCT04367350 COVID Sars-CoV2 Corona Virus Infection Myositis Myocarditis Diagnostic Test: laboratory biomarkers Diagnostic Test: muscle ultrasound MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome Myositis Myocarditis
HPO:Inflammatory myopathy Myocarditis Myositis
Primary Outcomes
Description: Elevation of creatine kinase during hyperacute phase of corona virus disease 2019 (Covid-19)
Measure: Rate of elevated creatine kinase in hyperacute phase Time: 1 week
Secondary Outcomes
Description: Elevation of creatine kinase during hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)
Measure: Rate of elevated creatine kinase Time: 24 months
Description: Two-peak elevation of creatine kinase during acute phase of corona virus disease 2019 (Covid-19)
Measure: Rate of two-peak elevation of creatine kinase during acute phase Time: 30 days
Description: Presence of myositis-specific antibodies on admission, at two weeks, and at end of follow-up
Measure: Rate of myositis-specific antibodies Time: 24 months
Description: Presence of antimyocardial antibodies on admission, at two weeks, and at end of follow-up
Measure: Rate of antimyocardial antibodies Time: 24 months
Description: Level of creatine kinase elevation in the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19) assessed by the area under the curve (AUC)
Measure: Area under the curve (AUC) of elevated creatine kinase Time: 24 months
Description: Maximal value of creatine kinase elevation in the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)
Measure: Peak-levels of elevated creatine kinase Time: 24 months
Description: Maximal value of troponin in the acute phase of corona virus disease 2019 (Covid-19)
Measure: Peak-levels of troponin Time: 30 days
Description: Maximal value of urine myoglobin in the acute of corona virus disease 2019 (Covid-19)
Measure: Peak-levels of urine myoglobin Time: 30 days
Description: Muscle hyperechogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score) during the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)
Measure: Rate of muscle hyperechogenicity Time: 24 months
Description: Peak-muscle hyperechogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score) during the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)
Measure: Peak-muscle hyperechogenicity Time: 24 months
2 Hospital Registry of Acute Myocarditis: Evolution of the Proportion of Positive SARS-COV-2 Cases During the Covid-19 Pandemic, Case Characteristics and Prognoses
Primary Outcomes
Description: Elevation of creatine kinase during hyperacute phase of corona virus disease 2019 (Covid-19)
Measure: Rate of elevated creatine kinase in hyperacute phase Time: 1 weekSecondary Outcomes
Description: Elevation of creatine kinase during hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)
Measure: Rate of elevated creatine kinase Time: 24 monthsDescription: Two-peak elevation of creatine kinase during acute phase of corona virus disease 2019 (Covid-19)
Measure: Rate of two-peak elevation of creatine kinase during acute phase Time: 30 daysDescription: Presence of myositis-specific antibodies on admission, at two weeks, and at end of follow-up
Measure: Rate of myositis-specific antibodies Time: 24 monthsDescription: Presence of antimyocardial antibodies on admission, at two weeks, and at end of follow-up
Measure: Rate of antimyocardial antibodies Time: 24 monthsDescription: Level of creatine kinase elevation in the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19) assessed by the area under the curve (AUC)
Measure: Area under the curve (AUC) of elevated creatine kinase Time: 24 monthsDescription: Maximal value of creatine kinase elevation in the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)
Measure: Peak-levels of elevated creatine kinase Time: 24 monthsDescription: Maximal value of troponin in the acute phase of corona virus disease 2019 (Covid-19)
Measure: Peak-levels of troponin Time: 30 daysDescription: Maximal value of urine myoglobin in the acute of corona virus disease 2019 (Covid-19)
Measure: Peak-levels of urine myoglobin Time: 30 daysDescription: Muscle hyperechogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score) during the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)
Measure: Rate of muscle hyperechogenicity Time: 24 monthsDescription: Peak-muscle hyperechogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score) during the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)
Measure: Peak-muscle hyperechogenicity Time: 24 monthsTo date, the effects of SARS-Cov-2 (Covid-19) on the myocardium and the role it plays in the evolution towards an acute myocarditis are badly understood. The current pandemic of this emerging virus is an opportunity to assess the proportion of acute myocarditis attributable to SARS-Cov-2(Covid-19) and to assess the clinical, biological and imaging presentations, by means of a national prospective multicentre hospital registry of cases of acute myocarditis.
NCT04375748 Acute Myocarditis Diagnostic Test: Performing routine care (clinical and paraclinical tests) Diagnostic Test: Examinations for the research: MeSH:Myocarditis
HPO:Myocarditis
Primary Outcomes
Description: Estimate at hospital discharge, over a period of 6 months, the evolution of the proportion of positive SARS-COV-2 cases among patients hospitalized for acute myocarditis in Intensive Cardiac Care Unit or Intensive Care Unit (polyvalent, surgical or medical), in the 19 hospitals participating in the study.
Measure: Evolution of the proportion of positive SARS-COV-2 cases. Time: 6 months.
Secondary Outcomes
Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort; Echocardiographic parameters: Volumes (mm3)
Measure: Ultrasound characteristics. Time: 1 year
Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: diameters (mm)
Measure: Ultrasound characteristics. Time: 1 year
Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort (Echocardiographic parameters: ventricular diastolic function (mm);
Measure: Ultrasound characteristics. Time: 1 year
Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort (Echocardiographic parameters: ventricular systolic function (mm);
Measure: Ultrasound characteristics. Time: 1 year
Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Left atrium volume (mm3);
Measure: Ultrasound characteristics. Time: 1 year
Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Maximum velocity of tricuspid valve insufficiency;
Measure: Ultrasound characteristics. Time: 1 year
Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Presence and quantification of a valvular regurgitation
Measure: Ultrasound characteristics. Time: 1 year
Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Presence of a pericardial effusion
Measure: Ultrasound characteristics. Time: 1 year
Description: Assess the short-term (30 days) and long-term (1 year) prognosis of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort. The 30-day prognosis will be defined in function to the outcome: A death, whatever the cause, A cardiovascular arrest with recovery, A cardiogenic shock, An acute lung oedema or One of the events cited above.
The 1-year prognosis will be defined in function to the outcome: A death, whatever the cause, The need to resort to transplantation and/or chronic assistance, A rehospitalization for cardiovascular reasons (heart failure, painful relapse, recovered cardiac arrest, myocarditis relapse, ACS), A myocarditis relapse, or one of the events cited above. The 1-year prognosis will also be defined in function to the New York Heart Association
(NYHA) class.
Measure: Assess prognosis of the acute myocarditis . Time: The short-term (30 days) and long-term (1 year).
Description: Identify the factors associated with a 30-day and 1-year prognosis of cases of acute myocarditis cardiovascular (Terminal heart failure, Acute edema of the lung, Cardiogenic shock, Sudden death / Ventricular rhythm disorder Pulmonary embolism, Aortic dissection Infectious endocarditis Stroke) or no cardiovascular (Acute respiratory syndrome, septic shock of non-cardiac origin, cancer, Public road accident, end-stage respiratory failure, insufficiency, end-stage renal Failure)
Measure: The factors associated with acute myocarditis cases . Time: The short-term (30 days) and long-term (1 year).
Description: Describe the biological parameters on admission and during the treatment (troponinemia (ng/ml)
Measure: Biological characteristics Time: 1 year
Description: Describe the biological parameters on admission and during the treatment NtproBNP(pg/ml)
Measure: Biological characteristics Time: 1 year
Description: Describe the biological parameters on admission and during the treatment CRP(mg/ml)
Measure: Biological characteristics Time: 1 year
Description: Ventricular volumes (ml)
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 year
Description: Systole Diameter
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 year
Description: Diastole Diameter
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 year
Description: Longitudinal deformation of left ventricle;
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 year
Description: Longitudinal deformation of right ventricle;
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 year
Description: Total volume of left ventricular oedema
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 year
Description: Quantification of T2 before contrast agent
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 year
Description: Quantification of T1 before contrast agent
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 year
Description: Perfusion anomalies
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 year
Description: Total volume of early left ventricular alteration
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 year
Description: Total volume of late left ventricular alteration
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 year
Description: Quantification of T1 after contrast agent
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 year
Description: Presence of a pericardial effusion
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 year
HPO Nodes
Primary Outcomes
Description: Estimate at hospital discharge, over a period of 6 months, the evolution of the proportion of positive SARS-COV-2 cases among patients hospitalized for acute myocarditis in Intensive Cardiac Care Unit or Intensive Care Unit (polyvalent, surgical or medical), in the 19 hospitals participating in the study.
Measure: Evolution of the proportion of positive SARS-COV-2 cases. Time: 6 months.Secondary Outcomes
Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort; Echocardiographic parameters: Volumes (mm3)
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: diameters (mm)
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort (Echocardiographic parameters: ventricular diastolic function (mm);
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort (Echocardiographic parameters: ventricular systolic function (mm);
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Left atrium volume (mm3);
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Maximum velocity of tricuspid valve insufficiency;
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Presence and quantification of a valvular regurgitation
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Presence of a pericardial effusion
Measure: Ultrasound characteristics. Time: 1 yearDescription: Assess the short-term (30 days) and long-term (1 year) prognosis of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort. The 30-day prognosis will be defined in function to the outcome: A death, whatever the cause, A cardiovascular arrest with recovery, A cardiogenic shock, An acute lung oedema or One of the events cited above. The 1-year prognosis will be defined in function to the outcome: A death, whatever the cause, The need to resort to transplantation and/or chronic assistance, A rehospitalization for cardiovascular reasons (heart failure, painful relapse, recovered cardiac arrest, myocarditis relapse, ACS), A myocarditis relapse, or one of the events cited above. The 1-year prognosis will also be defined in function to the New York Heart Association (NYHA) class.
Measure: Assess prognosis of the acute myocarditis . Time: The short-term (30 days) and long-term (1 year).Description: Identify the factors associated with a 30-day and 1-year prognosis of cases of acute myocarditis cardiovascular (Terminal heart failure, Acute edema of the lung, Cardiogenic shock, Sudden death / Ventricular rhythm disorder Pulmonary embolism, Aortic dissection Infectious endocarditis Stroke) or no cardiovascular (Acute respiratory syndrome, septic shock of non-cardiac origin, cancer, Public road accident, end-stage respiratory failure, insufficiency, end-stage renal Failure)
Measure: The factors associated with acute myocarditis cases . Time: The short-term (30 days) and long-term (1 year).Description: Describe the biological parameters on admission and during the treatment (troponinemia (ng/ml)
Measure: Biological characteristics Time: 1 yearDescription: Describe the biological parameters on admission and during the treatment NtproBNP(pg/ml)
Measure: Biological characteristics Time: 1 yearDescription: Describe the biological parameters on admission and during the treatment CRP(mg/ml)
Measure: Biological characteristics Time: 1 yearDescription: Ventricular volumes (ml)
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Systole Diameter
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Diastole Diameter
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Longitudinal deformation of left ventricle;
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Longitudinal deformation of right ventricle;
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Total volume of left ventricular oedema
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Quantification of T2 before contrast agent
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Quantification of T1 before contrast agent
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Perfusion anomalies
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Total volume of early left ventricular alteration
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Total volume of late left ventricular alteration
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Quantification of T1 after contrast agent
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Presence of a pericardial effusion
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 year